Advertisement
Chinese biotech Scizeng’s global licensing deal to yield up to US$1.44 billion
Yarrow Bioscience gets exclusive global rights for the GenSci098 therapy to treat thyroid eye disease and Graves’ disease
2-MIN READ2-MIN
1
Listen
A Chinese biopharmaceutical firm has sealed a global licensing deal valued at up to US$1.44 billion, the second in a week, as a wave of cross-border tie-ups shows no sign of abating despite headwinds from the US Biosecure Act.
Shanghai Scizeng Medical Technology, a unit of Changchun High-Tech Industry, has agreed to grant US-based Yarrow Bioscience exclusive global rights to develop, manufacture and commercialise GenSci098, an injectable therapy for thyroid eye disease and Graves’ disease, both of which are autoimmune conditions. The deal excludes mainland China, Hong Kong, Macau and Taiwan.
GenSci098 is currently undergoing clinical trials in mainland China and the US.
“This landmark partnership is a strategic step in our vision of becoming a global pharma innovator,” Dr Lei Jin, general manager of Changchun High-Tech, said in a statement, adding that GenSci098 had shown immense potential.
Select Voice
Select Speed
1x
AI-generated voice